Isoform-specific Modulation of Drug Metabolism in a Fatality Involving Olanzapine Overexposure: Inflammation-Induced Phenoconversion as a Mechanistic Framework

BACKGROUND: Interindividual variability influences adverse drug reactions and unexpected drug-related deaths. Despite increasing pharmacogenetics incorporation in clinical practice, acquired metabolic activity modifiers remain insufficiently integrated into toxicological interpretation. Here, the authors report an olanzapine overexposure fatality occurring despite therapeutic dosing, highlighting isoform-specific inflammation-induced phenoconversion. METHODS: A medico-legal investigation (including review of the medical file, full autopsy, toxicological [femoral blood and urine], and pharmacogenetic analyses [CYP1A2/2D6/2C8/2C9 and UGT1A4 genes]) was conducted in a 57-year-old woman hospitalized for bipolar disorder with psychotic features. She was administered titrated therapeutic does of olanzapine. RESULTS: The investigation indicated an acute systemic inflammatory state, characterized by neutrophilic leukocytosis (16 × 109/L) and elevated C-reactive protein (62 mg/L). A toxic femoral blood olanzapine concentration (172 mcg/L) and CYP1A2*30/*30, CYP2C8*1/*3, CYP2D*62/*5, and UGT1A4*1B/*1 genotypes were revealed by the toxicological and pharmacogenetics analyses, respectively. None of which alone accounted for the observed olanzapine accumulation. CONCLUSIONS: The selective accumulation of olanzapine, contrasted with preserved exposure to drugs predominantly metabolized by CYP3A4/2D6/alternative UGT isoforms, supports isoform-specific metabolic inhibition. CYP1A2 was the most plausible target of suppression. Although the impact of inflammation on UGT activity is less well characterized and appears isoform- and substrate-dependent, the selective modulation of UGT1A4 cannot be excluded. Overall, this case emphasizes that inflammation may differentially affect metabolic isoenzymes, and that both cytochrome P450- and UGT-mediated pathways should be considered when interpreting unexpected psychotropic drug overexposure.

Authors

Institutions

Publication Details

Journal
Therapeutic Drug Monitoring
Published
2026-11-02
DOI
https://doi.org/10.1097/ftd.0000000000001548
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Isoform-specific Modulation of Drug Metabolism in a Fatality Involving Olanzapine Overexposure: Inflammation-Induced Phenoconversion as a Mechanistic Framework

Marie B Briet, Chadi Abbara, Nicolas Picard, Stéphane Malbranque et al.
1 links
Therapeutic Drug Monitoring
Pharmacogenetics and Drug Metabolism
article

Isoform-specific Modulation of Drug Metabolism in a Fatality Involving Olanzapine Overexposure: Inflammation-Induced Phenoconversion as a Mechanistic Framework

Marie B Briet, Chadi Abbara, Nicolas Picard, Stéphane Malbranque, Guillaume Drevin, Nathalie Jousset, Maria Pena Martin, Florent Voillet
article en

Abstract

BACKGROUND: Interindividual variability influences adverse drug reactions and unexpected drug-related deaths. Despite increasing pharmacogenetics incorporation in clinical practice, acquired metabolic activity modifiers remain insufficiently integrated into toxicological interpretation. Here, the authors report an olanzapine overexposure fatality occurring despite therapeutic dosing, highlighting isoform-specific inflammation-induced phenoconversion. METHODS: A medico-legal investigation (including review of the medical file, full autopsy, toxicological [femoral blood and urine], and pharmacogenetic analyses [CYP1A2/2D6/2C8/2C9 and UGT1A4 genes]) was conducted in a 57-year-old woman hospitalized for bipolar disorder with psychotic features. She was administered titrated therapeutic does of olanzapine. RESULTS: The investigation indicated an acute systemic inflammatory state, characterized by neutrophilic leukocytosis (16 × 109/L) and elevated C-reactive protein (62 mg/L). A toxic femoral blood olanzapine concentration (172 mcg/L) and CYP1A2*30/*30, CYP2C8*1/*3, CYP2D*62/*5, and UGT1A4*1B/*1 genotypes were revealed by the toxicological and pharmacogenetics analyses, respectively. None of which alone accounted for the observed olanzapine accumulation. CONCLUSIONS: The selective accumulation of olanzapine, contrasted with preserved exposure to drugs predominantly metabolized by CYP3A4/2D6/alternative UGT isoforms, supports isoform-specific metabolic inhibition. CYP1A2 was the most plausible target of suppression. Although the impact of inflammation on UGT activity is less well characterized and appears isoform- and substrate-dependent, the selective modulation of UGT1A4 cannot be excluded. Overall, this case emphasizes that inflammation may differentially affect metabolic isoenzymes, and that both cytochrome P450- and UGT-mediated pathways should be considered when interpreting unexpected psychotropic drug overexposure.

Therapeutic Drug Monitoring
Centre National de la Recherche Scientifique (FR), Inserm (FR), Centre Hospitalier Universitaire d'Angers (FR), Centre Hospitalier Universitaire de Limoges (FR), Mitochondrial and Cardiovascular Physiopathology (FR), Université d'Angers (FR), Université de Limoges (FR)
Good health and well-being
Openalex Percentile: Top 12%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon